Brian Rini, MD
The ongoing phase III KEYNOTE-426 trial is investigating the safety and efficacy of the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) versus sunitinib (Sutent) alone in treatment-naive patients with advanced or metastatic renal cell carcinoma (RCC).
Brian Rini, MD, Cleveland Clinic, discussed the KEYNOTE-426 study and the promise of emerging combinations in RCC.
OncLive: Please provide some background for this ongoing trial.
In the field of kidney cancer, there are a lot of trials combining VEGF agents and immuno-oncology agents—that is one of the main facets of kidney cancer research right now. VEGF agents are the standard of care, immuno-oncology agents obviously are coming in and taking over a lot of cancers, including RCC. So, part of the rationale for the combination is that each drug by itself is active as monotherapy—VEGF agents, like axitinib, and checkpoint inhibitors, like pembrolizumab.
... to read the full story